PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PDIGREE
- 03 Jan 2019 Status changed from planning to not yet recruiting.
- 01 May 2017 According to an Exelixis media release, this trial is expected to start later in 2017.
- 01 Mar 2017 New trial record